Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Editas Medicine to $30 from $36 and keeps an Overweight rating on the shares. The firm highlights the momentum in RUBY study enrollment, which bodes well for the development timeline and market potential. Wells also reiterates its confidence in positive data from RUBY at midyear and 2023 updates, which should drive upside for shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
- Editas Medicine reports Q4 EPS (88c), consensus (80c)
- Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
- Editas Medicine initiated with an Overweight at Cantor Fitzgerald
- Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
